Autres langues Aligos Therapeutics, Inc.

Actions

ALGS

US01626L2043

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 08/09/2026			Varia. 5j.	Varia. 1 janv.
5,760 ^USD	-7,25%		-5,42%	-38,20%

12/08	Aligos Therapeutics lance les premiers dosages de l'étude de phase 1 sur l'ALG-170675 contre l'hépatite B chronique	CI
06/08	Aligos Therapeutics, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI

Autres langues

02/09	Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
12/08	Aligos Therapeutics Announces First Participant Dosed in the Phase 1 Study of its Potentially Best-in-Class Antisense Oligonucleotide ALG-170675 by its Partner Amoytop in China
12/08	Aligos Therapeutics Initiates Dosing in Phase 1 Study of Alg-170675 for Chronic Hepatitis B Virus Infection
06/08	Aligos Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
06/08	Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
30/07	Aligos Therapeutics to Announce 2nd Quarter 2026 Financial Results on August 6, 2026
13/07	Aligos Therapeutics Completes Enrollment In Phase 2 B-SUPREME Study Of Pevifoscorvir Sodium For Chronic HBV Infection
13/07	Aligos Therapeutics Completes Enrollment in Phase 2 Study of Potential Chronic Hepatitis B Treatment
13/07	Aligos Therapeutics Announces the Completion of Enrollment in the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium Under Development for the Treatment of Chronic HBV Infection
06/07	Aligos Gets $25 Million Upfront Payment From Licensing Deal
06/07	Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
06/07	Aligos Therapeutics, Inc. and Xiamen Amoytop Biotech Co., Ltd. Enter Exclusive License Deal for Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection
29/06	Aligos Therapeutics, Inc.(NasdaqCM:ALGS) added to Russell Microcap Value Benchmark Index
29/06	Aligos Therapeutics, Inc.(NasdaqCM:ALGS) added to Russell 3000E Index
29/06	Aligos Therapeutics, Inc.(NasdaqCM:ALGS) added to Russell Microcap Index
29/06	Aligos Therapeutics, Inc.(NasdaqCM:ALGS) added to Russell 3000E Value Benchmark
27/05	Aligos Therapeutics Presents Positive Data at the EASL Congress 2026
27/05	Aligos Therapeutics, Inc. Presents Positive Data On Pevifoscorvir Sodium And Pipeline Programs At EASL Congress 2026
13/05	Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026
08/05	Aligos Therapeutics : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)
07/05	Aligos Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
07/05	Aligos Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results
30/04	Aligos Therapeutics to Announce 1st Quarter 2026 Financial Results on May 7, 2026
27/04	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/04	Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)